Skip to main content
. 2019 Aug 1;9(8):1796–1814.

Figure 1.

Figure 1

Bevacizumab promoted the invasion, migration of TNBC cells, and increased percent of ALDH1+ TNBC cells. (A) Microscopic views from transwell assay to estimate MDA-MB-231/MDA-MB-468 cells invasion following 24 h treatment of Bevacizumab (200 nM), bar = 100 μm. (B) Quantitative analysis of (A) by Image J. (C) Photomicrographs of cell migration from wound healing assay in MDA-MB-231/MDA-MB-468 cells treated with Bevacizumab, bar = 100 μm. (D) MDA-MB-231/MDA-MB-468 cells were treated with Bevacizumab for 24 h, then ALDH1+ cells were determined by Alderfluor assay and viable cells (7-AAD negative) were used for analysis. DEAB-treated cells were used as negative control. (E) Quantitative analysis of (C) by Image J. (F) Quantitative analysis of (D). Data were presented as the mean ± SD, n = 3, *P < 0.05, **P < 0.01 (MDA-MB-231 cells); #P < 0.05, ##P < 0.01 (MDA-MB-468 cells).